Suchergebnisse - "Kazandjian, Dickran"

PubPharm (64)

1

Minimal Residual Disease-Adapted Therapy in Multiple Myeloma : Current Evidence and Opinions

enthalten in: Current oncology reports | 2024

von Meseha, M. | Hoffman, J. | Kazandjian, D. | +2

2

Genomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple Myeloma

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2024

von Kazandjian, D. | Diamond, B. | Papadimitriou, M. | +16

3

Genomic Classification and Individualized Prognosis in Multiple Myeloma

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Maura, F. | Rajanna, A. | Ziccheddu, B. | +34

4

Emerging Strategies for the Prevention of Immune Toxicities Associated with T cell-Engaging Cancer Therapies

enthalten in: Blood cancer discovery | 2024

von Kowalski, A. | Lykon, J. | Diamond, B. | +6

5

Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens

enthalten in: Nature cancer | 2023

von Maura, F. | Boyle, E. | Coffey, D. | +34

6

Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma

enthalten in: Nature communications | 2023

von Coffey, D. | Maura, F. | Gonzalez-Kozlova, E. | +20

7

T cell redirecting bispecific antibodies for multiple myeloma : emerging therapeutic strategies in a changing treatment landscape

enthalten in: Leukemia & lymphoma | 2022

von Kazandjian, D. | Kowalski, A. | Landgren, O.

8

Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)

enthalten in: NPJ precision oncology | 2022

von Nguyen, N. | Chaudhry, S. | Totiger, T. | +16

9

Efficacy and safety of carfilzomib-lenalidomide-dexamethasone in newly diagnosed multiple myeloma : pooled analysis of four single-arm studies

enthalten in: Leukemia & lymphoma | 2022

von Landgren, O. | Kazandjian, D. | Roussel, M. | +7

10

Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma

enthalten in: Nature communications | 2022

von Yang, Y. | Bolomsky, A. | Oellerich, T. | +23

ErratumIn: Nat Commun. 2022 Oct 3;13(1):5830. - PMID 36192480

1
2
3
4
5
6
7
Nächster »
[7]